Iradimed (IRMD) Liabilities and Shareholders Equity (2013 - 2026)

Iradimed (IRMD) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $115.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 8.01% year-over-year to $115.0 million in Q2 2026; TTM through Jun 2026 was $452.9 million, a 13.0% increase from a year earlier, with the FY2025 full-year figure at $108.8 million, up 10.63% from the prior year.
• Liabilities and Shareholders Equity was $115.0 million for Q2 2026 at Iradimed, up from $114.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $115.0 million in Q2 2026 and troughed at $72.4 million in Q1 2022.
• A 5-year average of $93.4 million and a median of $91.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity grew 0.19% in 2022 and rose 21.72% in 2025, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $85.5 million in 2022, then grew by 7.77% to $92.2 million in 2023, then increased by 6.7% to $98.3 million in 2024, then rose by 10.63% to $108.8 million in 2025, then gained by 5.7% to $115.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $115.0 million (Q2 2026), $114.4 million (Q1 2026), and $108.8 million (Q4 2025), per Business Quant data.